

DAFTAR PUSTAKA

1. Nezic D, Spasic T, Micovic S, Kosevic D, Balevic M, Petrovic I, et al. Clinical performances of the EuroSCORE II in a single-centre, contemporary cardiac surgical cohort. *J Cardiothorac Surg.* 2015;10(S1):11000.
2. Priyantoro K, Soerianata S. Non surgical management of unprotected isolated ostial left main coroner artery disease. *J Kardiol Indones.* 2012;33(3):166–73.
3. Melly L, Torregrossa G, Lee T, Jansens JL, Puskas JD. Fifty years of coronary artery bypass grafting. *J Thorac Dis.* 2018;10(3):1960–7.
4. Gutacker N, Bloor K, Cookson R, Gale CP, Maynard A, Pagano D, et al. Hospital surgical volumes and mortality after coronary artery bypass grafting: using international comparisons to determine a safe threshold. *Health Serv Res.* 2017;52(2):863–78.
5. Harahap G, Nurcahyo W, Ismail A. Mortalitas operasi jantung coronary artery bypass graft di Rsup Dr Kariadi Semarang periode Januari 2014 - Desember 2014. *J Kedokt Diponegoro.* 2016;5(2):160–6.
6. Ariaty GM, Sudjud RW, Sitanggang RH. Angka mortalitas pada pasien yang menjalani bedah pintas koroner berdasar Usia, jenis kelamin, left ventricular ejection fraction, cross clamp time, cardio pulmonary bypass time, dan penyakit penyerta. *J Anestesi Perioper.* 2017;5(5):155–62.
7. Farouk Musa A, Cheong XP, Dillon J, Nordin R Bin. Validation of euroSCORE II in patients undergoing coronary artery bypass grafting (Cabg) surgery at the national heart institute, kuala lumpur: A retrospective review. [version 1; peer review: 1 approved, 1 approved with reservations]. *F1000Research.* 2018;7:1–18.
8. Rianda RA, Semedi BP, Subagjo A, Avidar YP. EuroSCORE II as predictor of mortality and morbidity in post-CABG Patient in Dr. Soetomo General Academic Hospital. *Indones J Anesthesiol Reanim.* 2022;4(1):14.
9. Janikowski K, Morawiec R, Jegier B, Jaszewski R, Lelonek M. EuroSCORE II does not show better accuracy nor predictive power in comparison to original EuroSCORE: A single-centre study. *Kardiol Pol.* 2016;74(5):469–75.
10. Sembiring YE, Ginting A, Puruhito, Budiono. Validation of euroscore ii to predict

- mortality in post-cardiac surgery patients in east java tertiary hospital. *Med J Indones.* 2021;30(1):54–9.
11. Ranjan R, Adhikary D, Mandal S, Saha SK, Hasan K, Adhikary AB. Performance of EuroSCORE II and logistic EuroSCORE in Bangladeshi population undergoing off-pump coronary artery bypass surgery: A prospective cohort study. *JRSM Cardiovasc Dis* [Internet]. 2019;8:204800401986212. Tersedia pada: <https://doi.org/10.1177/2048004019862125>
 12. Diodato M, Chedrawy EG. Coronary artery bypass graft surgery: The past, present, and future of myocardial revascularisation. *Surg Res Pract.* 2014;2014:1–6.
 13. Islam MY, Ahmed MU, Khan MS, Bawany FI, Khan A, Arshad MH. On pump coronary artery bypass graft surgery versus off pump coronary artery bypass graft surgery: a review. *Glob J Health Sci.* 2014;6(3):186–93.
 14. Shekar PS. On-pump and off-pump coronary artery bypass grafting. *Circulation.* 2006;113(4):51–2.
 15. Bachar B, Manna B. Coronary artery bypass graft. Treasure Island (FL): StatPearls Publishing; 2021.
 16. Montrieff T, Koyfman A, Long B. Coronary artery bypass graft surgery complications: A review for emergency clinicians. *Am J Emerg Med* [Internet]. 2018;36(12):2289–97. Tersedia pada: <https://doi.org/10.1016/j.ajem.2018.09.014>
 17. Hussain SMA, Harky A. Complications of coronary artery bypass grafting. *Int J Med Rev.* 2019;6(1):1–5.
 18. Ribera A, Ferreira-González I, Cascant P, Pons JMV, Permanyer-Miralda G. Evaluation of risk-adjusted hospital mortality after coronary artery bypass graft surgery in the catalan public healthcare system influence of hospital management type (ARCA Study). *Rev Española Cardiol (English Ed.* 2006;59(5):431–40.
 19. Head SJ, Milojevic M, Daemen J, Ahn JM, Boersma E, Christiansen EH, et al. Mortality after coronary artery bypass grafting versus percutaneous coronary intervention with stenting for coronary artery disease: a pooled analysis of individual patient data. *Lancet.* 2018;391(10124):939–48.
 20. Hardiman SC, Villan Villan YF, Conway JM, Sheehan KJ, Sobolev B. Factors affecting mortality after coronary bypass surgery: a scoping review. *J Cardiothorac*

- Surg [Internet]. 2022;17(1):1–14. Tersedia pada: <https://doi.org/10.1186/s13019-022-01784-z>
21. Hung DQ, Minh NT, Vo HL, Hien NS, Tuan NQ. Impact of pre-, intra-and post-operative parameters on in-hospital mortality in patients undergoing emergency coronary artery bypass grafting: A scarce single-center experience in resource-scare setting. *Vasc Health Risk Manag.* 2021;17(April):211–26.
 22. Ali Kamal Y, Al-Elwany S, Ghoneim A, El-Minshawy A. Traditional predictors of in-hospital mortality after coronary artery bypass grafting: Current status. *Cardiothorac Vasc Sci.* 2017;1(2):1–5.
 23. Gaudino M, Hameed I, Farkouh ME, Rahouma M, Naik A, Robinson NB, et al. Overall and Cause-Specific Mortality in Randomized Clinical Trials Comparing Percutaneous Interventions with Coronary Bypass Surgery: A Meta-analysis. *JAMA Intern Med.* 2020;180(12):1638–46.
 24. Bulow NMH, Colpo E, Duarte MF, Correa EFM, Schlosser RS, Lauda A, et al. Inflammatory response in patients under coronary artery bypass grafting surgery and clinical implications: a review of the relevance of dexmedetomidine Use. *ISRN Anesthesiol.* 2014;2014:1–28.
 25. Ren YS, Li LF, Peng T, Tan YJ, Sun Y, Cheng GL, et al. The effect of milrinone on mortality in adult patients who underwent CABG surgery: a systematic review of randomized clinical trials with a meta-analysis and trial sequential analysis. *BMC Cardiovasc Disord.* 2020;20(1):1–16.
 26. Newman MF, Ferguson TB, White JA, Ambrosio G, Koglin J, Nussmeier NA, et al. Effect of adenosine-regulating agent acadesine on morbidity and mortality associated with coronary artery bypass grafting: The RED-CABG randomized controlled trial. *JAMA - J Am Med Assoc.* 2012;308(2):157–64.
 27. Kusuma DI, Jatmiko HD. Penilaian praoperasi bedah jantung preoperative assessment of cardiac surgery. *J Anesthesiol Indones.* 2018;10(3):175–87.
 28. Nashef SAM, Roques F, Sharples LD, Nilsson J, Smith C, Goldstone AR, et al. Euroscore II. *Eur J Cardio-thoracic Surg.* 2012;41(4):734–45.
 29. Biancari F, Vasques F, Mikkola R, Martin M, Lahtinen J, Heikkinen J. Validation of EuroSCORE II in patients undergoing coronary artery bypass surgery. *Ann Thorac*

- Surg [Internet]. 2012;93(6):1930–5. Tersedia pada: <http://dx.doi.org/10.1016/j.athoracsur.2012.02.064>
30. Kar P, Geeta K, Durga RGP. Mortality prediction in Indian cardiac surgery patients: Validation of European System for Cardiac Operative Risk Evaluation II. *Indian J Anaesth.* 2017;61(4):157–62.
 31. Gao F, Shan L, Wang C, Meng X, Chen J, Han L, et al. Predictive ability of european heart surgery risk assessment system ii (Euroscore ii) and the society of thoracic surgeons (sts) score for in-hospital and medium-term mortality of patients undergoing coronary artery bypass grafting. *Int J Gen Med.* 2021;14(November):8509–19.
 32. Nicolini F, Fortuna D, Contini GA, Pacini D, Gabbieri D, Zussa C, et al. The impact of age on clinical outcomes of coronary artery bypass grafting: Long-term results of a real-world registry. *Biomed Res Int.* 2017;2017.
 33. Maraschini A, Seccareccia F, D'Errigo P, Rosato S, Badoni G, Casali G, et al. Role of gender and age on early mortality after coronary artery bypass graft in different hospitals: Data from a national administrative database. *Interact Cardiovasc Thorac Surg.* 2010;11(5):537–42.
 34. Mannacio VA, Mannacio L. Sex and mortality associated with coronary artery bypass graft. *J Thorac Dis.* 2018;10(Suppl 18):S2157–9.
 35. . Md. Alauddin, Tareq MZ, Md. Tareq Morshed AJ, Aslam MM, Joshi D, . N, et al. Comparison of the Characteristics and Outcomes of Patients Undergoing Concurrent CABG with MVR. *Sch J Appl Med Sci.* 2020;8(12):2783–8.
 36. Chan PG, Seese L, Aranda-Michel E, Sultan I, Gleason TG, Wang Y, et al. Operative mortality in adult cardiac surgery: Is the currently utilized definition justified? *J Thorac Dis.* 2021;13(10):5582–91.
 37. Ullah W, Gul S, Saleem S, Syed MA, Khan MZ, Zahid S, et al. Trend, predictors, and outcomes of combined mitral valve replacement and coronary artery bypass graft in patients with concomitant mitral valve and coronary artery disease: a National Inpatient Sample database analysis. *Eur Hear J Open.* 2022;2(1):1–11.
 38. Kurniawaty J, Setianto BY, Widyastuti Y, Supomo S, Boom CE, Ancilla C. Validation for EuroSCORE II in the Indonesian cardiac surgical population: a retrospective, multicenter study. *Expert Rev Cardiovasc Ther [Internet].* 2022;20(6):1–6. Tersedia

pada: <https://doi.org/10.1080/14779072.2022.2078703>

39. Liakopoulos OJ, Schlachtenberger G, Wendt D, Choi YH, Slottosch I, Welp H, et al. Early Clinical Outcomes of Surgical Myocardial Revascularization for Acute Coronary Syndromes Complicated by Cardiogenic Shock: A Report From the North-Rhine-Westphalia Surgical Myocardial Infarction Registry. *J Am Heart Assoc.* 2019;8(10).
40. Shaefi S, O’Gara B, Kociol RD, Joynt K, Mueller A, Nizamuddin J, et al. Effect of cardiogenic shock hospital volume on mortality in patients with cardiogenic shock. *J Am Heart Assoc.* 2015;4(1):1–9.
41. Tehrani S, Malik A, Hausenloy DJ. Cardiogenic shock and the ICU patient 2C04 3C00. *J Intensive Care Soc.* 2013;14(3):235–43.
42. Levine AB, Punahaole D, Levine TB. Characterization of the role of nitric oxide and its clinical applications. *Cardiol.* 2012;122(1):55–68.

LAMPIRAN TABEL DAN GAMBAR

Tabel 1. Karakteristik sampel


Karakteristik		<i>Non survive</i> n=29	<i>Survive</i> n=152	P Value
Umur (Mean ± SD)		55,76±10,14	57,09±9,23	0,942 ^a
Jenis Kelamin	Laki-laki (%)	22 (75,9)	126 (82,9)	0,369 ^b
	Perempuan (%)	7 (24,1)	26 (17,1)	
Diagnosis	CAD 1 VD (%)	0 (0,0)	1 (0,7)	0,000 ^{b**}
	CAD 2 VD (%)	1 (3,4)	10 (6,6)	
	CAD 3 VD (%)	23 (79,3)	141 (92,8)	
	CAD 3 VD + MVR (%)	5 (17,2)	0 (0,0)	

Data ditampilkan dengan mean±standar deviasi. (a): Data dianalisa dengan uji *Mann Whitney*. (b): Data dianalisa dengan uji chi-square. **: *significant different p < 0,001*.

Tabel 2. Hubungan EuroSCORE II dengan mortalitas

Mortalitas	n	Min	Max	Mean ± SD	P-value
Non survive	29	1,35	10,10	3,87 ± 2,65	0,000**
Survive	152	0,55	2,64	0,89 ± 0,37	

Data ditampilkan dengan mean±standar deviasi. Data dianalisa dengan uji *Mann Whitney*. **: *significant different p < 0,001*.



Gambar 1. Kurva AUC (ROC Curve) EuroSCORE II dan mortalitas

Tabel 3. Hasil analisis ROC Curve pada EuroSCORE II dan mortalitas pasien post operasi CABG

Keterangan	Nilai
AUC (ROC)	0,985
Sensitivitas	100%
Spesifisitas	91,4%
Cut-off	1,30%

Tabel 4. Analisis tabulasi silang berdasarkan kategori EuroSCORE II

EuroSCORE II (%)	<i>Non survive (n)</i>		<i>Survive (n)</i>		Total
	<i>Expected</i>	<i>Observed</i>	<i>Expected</i>	<i>Observed</i>	
0,00-0,55	0,062	0	14,938	15	15
0,56-0,58	0,097	0	21,903	22	22
0,59-0,76	0,163	0	20,837	21	21
0,77-0,79	0,186	0	18,814	19	19
0,80-0,91	0,297	0	20,703	21	21
0,92-1,01	0,403	0	18,597	19	19
1,02-1,25	0,638	0	17,362	18	18
1,26-1,85	2,797	6	15,203	12	18
1,86-3,24	14,361	13	3,639	5	18
3,25-10,10	9,996	10	0,004	0	10

Data ditampilkan dengan jumlah pasien. Data dianalisa dengan analisis regresi logistik ganda dan uji Hosmer dan Lemeshow.

Tabel 5. Faktor penyebab mortalitas pasien post operasi CABG

Penyebab mortalitas	n	%
Syok Hipovolemik	5	17,24
Syok Kardiogenik	22	75,86
Syok Sepsis	2	6,89
Total	29	100,00

REKOMENDASI PERSETUJUAN ETIK



KEMENTERIAN PENDIDIKAN, KEBUDAYAAN, RISET DAN TEKNOLOGI
 UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN
 KOMITE ETIK PENELITIAN UNIVERSITAS HASANUDDIN
 RSPTN UNIVERSITAS HASANUDDIN
 RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR
 Sekretariat : Lantai 2 Gedung Laboratorium Terpadu
 JL.PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245.
 Contact Person: dr. Agussalim Bukhari.,MMed,PhD., SpGK TELP. 081241850858, 0411 5780103, Fax : 0411-581431



REKOMENDASI PERSETUJUAN ETIK

Nomor : 557/UN4.6.4.5.31/ PP36/ 2022

Tanggal: 4 Oktober 2022

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH22090544	No Sponsor Protokol	
Peneliti Utama	dr.Mochammad Riyadi	Sponsor	
Judul Peneliti	HUBUNGAN ANTARA EURO SCORE II TERHADAP MORTALITAS PADA PASIEN POST OPERASI CABG DI ICU PUSAT JANTUNG TERPADU RSUP DR. WAHIDIN SUDIROHUSODO		
No Versi Protokol	1	Tanggal Versi	19 September 2022
No Versi PSP		Tanggal Versi	
Tempat Penelitian	RSUP Dr. Wahidin Sudirohusodo Makassar		
Jenis Review	<input type="checkbox"/> Exempted <input checked="" type="checkbox"/> Expedited <input type="checkbox"/> Fullboard Tanggal	Masa Berlaku 4 Oktober 2022 sampai 4 Oktober 2023	Frekuensi review lanjutan
Ketua KEP Universitas Hasanuddin	Nama Prof.Dr.dr. Suryani As'ad, M.Sc.,Sp.GK (K)	Tanda tangan	
Sekretaris KEP Universitas Hasanuddin	Nama dr. Agussalim Bukhari, M.Med.,Ph.D.,Sp.GK (K)	Tanda tangan	

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Laporan SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari protokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan